Japan marks latest approval for Bayer's riociguat
This article was originally published in Scrip
Executive Summary
Japan's Ministry of Health, Labour and Welfare (MHLW) has granted approval to Bayer Healthcare's Adempas (riociguat) for the treatment of adults with inoperable chronic-thromboembolic pulmonary hypertension (CTEPH) or persistent or recurrent CTEPH after surgical treatment.